Pharmacological discrimination between muscarinic receptor signal transduction cascades with bethanechol chloride
Liwang Liu,Ann R Rittenhouse
DOI: https://doi.org/10.1038/sj.bjp.0705157
IF: 7.3
2003-04-01
British Journal of Pharmacology
Abstract:Muscarinic agonist specificity is limited, making it difficult to match receptor subtypes with signal transduction cascades that mediate ion channel modulation. We have characterized the inhibitory effects of two muscarinic agonists, oxotremorine‐M (Oxo‐M) and bethanechol chloride (BeCh), on Ca2+ currents in neonatal rat superior cervical ganglion neurons. Oxo‐M‐mediated (10 μM) inhibition occurred via two signaling pathways. The first pathway inhibited whole cell peak currents, consisting primarily of N‐type current, but not FPL 64176‐induced, long‐lasting tail currents, comprised entirely of L‐type current. Inhibited currents displayed slowed activation kinetics and voltage dependence, characteristics of membrane‐delimited inhibition. Current inhibition was blocked by the selective M2 receptor antagonist, methoctramine (METH; 100 nM), or following pertussis toxin (PTX) pretreatment. Activation of the second pathway inhibited both peak and long‐lasting tail currents. This pathway was voltage‐independent, PTX‐insensitive, but sensitive to internal Ca2+ chelator concentration. Muscarinic toxin 7 (MT‐7, 100 nM), an irreversible M1 receptor antagonist, eliminated this inhibition. Oxo‐M (100 μM) decreased L‐ and N‐type channel activities in cell‐attached patches, indicating that a diffusible second messenger is involved. BeCh (100 μM) also inhibited whole cell currents via the membrane‐delimited pathway. Blocking M4 receptors with 100 nM pirenzepine (in the presence of MT‐7) had no effect, while antagonizing M2 receptors with METH abolished inhibition. Concentrations of BeCh as high as 3 mM failed to inhibit either peak or long‐lasting tail currents following PTX pretreatment. These results indicate that BeCh may be an effective tool for selectively activating M2 receptor stimulation of the membrane‐delimited pathway. British Journal of Pharmacology (2003) 138, 1259–1270. doi:10.1038/sj.bjp.0705157
pharmacology & pharmacy